MedTrace Logo

Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD

NCT05576428 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-28

No results posted yet for this study

Summary

Currently researches are focusing on the effect of antioxidants in the treatment of non-alcoholic fatty liver disease (NAFLD). Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes.

Conditions

  • NAFLD

Interventions

BEHAVIORAL

Diet and exercise

diet and exercise in patients of NAFLD

DRUG

NAC with diet and exercise

NAC with diet and exercise in patients of NAFLD

Sponsors & Collaborators

  • Dow University of Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-04-30
Completion
2023-05-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05576428 on ClinicalTrials.gov